Zelluna Taps Medpace for First-in-Human Trial of MAGE-A4-Targeting Cell Therapy
Event summary
- Zelluna has selected Medpace as its CRO partner for the Phase 1 trial of ZIMA-101, its lead TCR-NK cell therapy targeting MAGE-A4.
- The trial will evaluate safety and early efficacy in patients with advanced solid cancers, with data expected from mid-2026.
- Medpace will provide comprehensive clinical development services, including trial management, regulatory support, and data analysis.
- Zelluna submitted its Clinical Trial Application to the UK MHRA in December 2025.
The big picture
Zelluna's partnership with Medpace marks a critical transition from preclinical to clinical-stage development, a pivotal step for biotech companies aiming to bring novel therapies to market. The trial of ZIMA-101, the world's first MAGE-A4-targeting TCR-NK therapy, could set a precedent for off-the-shelf cell therapies in solid cancers, an area with significant unmet medical needs. The collaboration underscores the growing reliance on specialized CROs to navigate the regulatory and operational challenges of advanced cell therapy trials.
What we're watching
- Clinical Validation
- How initial data from the ZIMA-101 trial will validate Zelluna's TCR-NK platform and its potential in solid tumors.
- Regulatory Progress
- The pace at which Zelluna secures MHRA approval to initiate the Phase 1 study.
- Execution Risk
- Whether Medpace's expertise can mitigate the complexities of executing a first-in-human cell therapy trial.
Related topics